Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis
Journal of the American College of Cardiology2015Vol. 66(21), pp. 2451–2466
Citations Over TimeTop 1% of 2015 papers
Morie A. Gertz, Merrill D. Benson, P. James B. Dyck, Martha Grogan, T. Coelho, Márcia Waddington‐Cruz, John L. Berk, Violaine Planté‐Bordeneuve, Hartmut Schmidt, Giampaolo Merlini
Abstract
Transthyretin amyloidosis is a fatal disorder that is characterized primarily by progressive neuropathy and cardiomyopathy. It occurs in both a mutant form (with autosomal dominant inheritance) and a wild-type form (with predominant cardiac involvement). This article guides clinicians as to when the disease should be suspected, describes the appropriate diagnostic evaluation for those with known or suspected amyloidosis, and reviews the interventions currently available for affected patients.
Related Papers
- → Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation(2007)131 cited
- → Spinal multifocal amyloidosis derived from wild-type transthyretin(2011)25 cited
- → 532 Long-Term Outcome in Patients Treated with Combined Heart- and Liver Transplantation for Familial Amyloidotic Cardiomyopathy(2011)4 cited
- → Systemic transtiretin amyloidosis in the elderly patient with recurrent pleural effusions(2021)1 cited
- → Structurally abnormal transthyretin causing familial amyloidotic polyneuropathy in Sweden(1987)28 cited